A retrospective study of Lutonix 035 Drug Coated Balloon (DCB) and In.Pact DCBs in patients with symptomatic peripheral artery disease undergoing femoropopliteal intervention.

Trial Profile

A retrospective study of Lutonix 035 Drug Coated Balloon (DCB) and In.Pact DCBs in patients with symptomatic peripheral artery disease undergoing femoropopliteal intervention.

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Feb 2016

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Peripheral arterial disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Feb 2016 New trial record
    • 09 Feb 2016 According to a Bard Peripheral Vascular Inc. media release results of retrospective study of Lutonix 035 Drug Coated Balloon (DCB) and In.Pact DCBs in patients with symptomatic peripheral artery disease undergoing were presented at Leipzig International Course (LINC).
    • 09 Feb 2016 Results published in the Bard Peripheral Vascular Inc. media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top